Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for postoperative cognition and anesthesia recovery in elderly surgical patients
ChiCTR2200055894Phase 4Not yet recruiting
- Sponsor
- 925th Hospital of the Joint Logistic Support Force
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of esketamine in post-operative cognitive decline (POCD) (3 arms), sponsored by 925th Hospital of the Joint Logistic Support Force. Primary endpoints: Postoperative cognitive function, Respiratory recovery time after anesthesia and 4 more. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
post-operative cognitive decline (POCD)
Beyond the preview
Go deeper on ChiCTR2200055894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055894.